title: Comparative studies on the evaluation of the effect of new anthelminthics on various intestinal helminthiasis in Iran. Effects of anthelminthics on intestinal helminthiasis.
abstract: The effect of pyrantel pamoate, levamisole, mebendazole, thiabendazole and bephenium hydroxynaphthoate on various intestinal helminths were evaluated among the inhabitants of four villages in the Dezful area southwest of Iran. A total number of 328 persons, all infected simultaneously with Ascaris and hookworm (Ancylostoma duodenale) and 49.2% with Trichostrongylus spp., were randomly divided into six groups. One group was kept as the control and the other five were each treated with one compound. Follow-up examinations showed that all of the drugs used were highly effective on Ascaris, and the differences in the cure rate were not statistically significant except for bephenium hydroxynaphthoate which showed a lower cure rate. For hookworm, cure rates of 100, 90, and 85% were observed with levamisole, pyrantel pamoate and bephenium hydroxynaphthoate, respectively. Cure rates observed with mebendazole and thiabendazole were 35 and 51%, respectively. For Trichostrongylus, the highest cure rate was achieved with levamisole, followed by thiabendazole and mebendazole. While the percentage of people showing side-effects was rather low for all drugs, thiabendazole and bephenium hydroxynaphthoate produced a higher, and levamisole a lower, percentage of side effects.
mesh_terms: D000293:Adolescent; D000328:Adult; D000724:Ancylostomiasis / Q000188:drug therapy; D000871:Anthelmintics / Q000627:therapeutic use*; D001196:Ascariasis / Q000188:drug therapy; D001598:Bephenium Compounds / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005243:Feces / Q000469:parasitology; D005500:Follow-Up Studies; D006373:Helminthiasis / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D007492:Iran; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use; D008463:Mebendazole / Q000009:adverse effects / Q000627:therapeutic use; D010270:Parasite Egg Count; D011716:Pyrantel Pamoate / Q000009:adverse effects / Q000627:therapeutic use; D013827:Thiabendazole / Q000009:adverse effects / Q000627:therapeutic use; D014253:Trichostrongylosis / Q000188:drug therapy
chemical_list: D000871:Anthelmintics; D001598:Bephenium Compounds; D007978:Levamisole; D011716:Pyrantel Pamoate; D008463:Mebendazole; D013827:Thiabendazole